KODIAK SCIENCES INC. Debt Securities, Available-for-sale, Amortized Cost
KODIAK SCIENCES INC. (KOD) had Debt Securities, Available-for-sale, Amortized Cost of $23.55 million as of 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Notes › Debt Securities, Available-for-Sale, Amortized Cost
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2019-11-12
- 2019-09-30: Debt Securities, Available-for-sale, Amortized Cost $23.55M.
- 2019-06-30: Debt Securities, Available-for-sale, Amortized Cost $23.12M.
- 2019-03-31: Debt Securities, Available-for-sale, Amortized Cost $23.85M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2019-09-30 | $23.55M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $23.12M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $23.85M 10-Q · filed 2019-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |